Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine :: Nuclear medicine
 
S. Graf, M. Nikfardjam, A. Khorsand, S. Ofluoglu, S. Nekolla, R. Dudczak, G. Maurer, K. Kletter, K. Huber, C. Pirich

13 N-ammonia rest/stress PET: Folic acid improves global coronary vasoreactivity in coronary artery disease patients with normal or elevated homocysteine levels

Keywords: homocysteine, coronary flow reserve, coronary artery disease, Positron emission tomography

AIM: Hyperhomocysteinaemia (Hhcy) is known to be an independent risk factor for vascular disease. Coronary flow reserve (CFR) measured by positron emission tomography (PET) is a sensitive method to monitor the effects of pharmacologic interventions in Hhcy. We assessed coronary vascular reactivity by PET in patients with coronary artery disease (CAD) dependent on their homocysteine (Hcy) levels before and under high dose folic acid supplementation therapy (FAST). PATIENTS, METHODS: Twelve patients with CAD underwent rest/adenosine 13 N-ammonia PET for quantification of myocardial blood flow (MBF) and CFR before and after nine weeks FAST (10 mg/day). RESULTS: Folate levels increased from 21 6 to 210 34 g/l (+900%, p < 0.0001) while Hcy levels decreased from 12.1 3.6 to 9.1 3.1 mol/l ( - 25%; p < 0.01). Global resting MBF remained nearly unchanged after FAST, while stress MBF (from 2.61 0.93 to 3.25 1.15 ml/g/min; p = 0.05) and CFR (from 3.00 0.76 to 3.72 0.93 ml/g/min; p < 0.05; +24%) significantly increased in patients with normal and elevated Hcy levels (cut off 12 mol/l). An inverse relation was found between Hcy and CFR (R = - 0.53; p = 0.08) and between Hcy and MBF at rest (R = - 0.62; p < 0.05) at baseline conditions, not persisting after FAST. CONCLUSION: Coronary vascular reactivity can be improved by FAST in patients with CAD and normal or elevated Hcy levels. FAST might lower an increased cardiovascular risk in CAD patients possibly by mechanisms that are not related to Hcy.

Nuklearmedizin, Schattauer

Print ISSN: 0029-5566
Volume: 45, 01/2006
Pages: 248 - 253

Show full article (external site)

Show all available items of this journal